SEC Filing Summary: Skillz Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Skillz Inc. (NYSE: SKLZ) on December 20, 2022, reporting an event that occurred on December 16, 2022. The filing addresses a regulatory notice regarding the company's continued listing status on the New York Stock Exchange (NYSE).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice: the average closing price of the Company's Class A common stock was less than $1.00 over a consecutive 30 trading-day period.
Material Changes
On December 16, 2022, the NYSE notified Skillz Inc. that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual due to the low stock price. This notice does not result in immediate delisting but initiates a compliance period.
Outlook, Management Commentary, and Risks
- Cure Period: The Company has a six-month period following the notice to regain compliance. Compliance can be achieved if the closing share price is at least $1.00 and the 30-day average closing price is at least $1.00 on the last trading day of any calendar month during this period.
- Proposed Actions: Management intends to consider alternatives to cure the deficiency, including a reverse stock split, subject to stockholder approval at the next annual meeting.
- Trading Status: The Class A common stock will continue to be listed and trade on the NYSE during the cure period, provided other listing standards are met.
- Risk: Failure to cure the deficiency within the specified timeframe could result in delisting.
Investor Verification Checklist
- Verify the current stock price and 30-day average to assess immediate compliance status.
- Monitor upcoming announcements regarding the potential reverse stock split and the date of the next annual stockholder meeting.
- Review the press release dated December 20, 2022 (Exhibit 99.1) for additional management commentary.
- Track the company's progress toward the January 3, 2023, deadline to notify the NYSE of its intent to cure the deficiency.